Pharmaceutical Aspects of Nanocarriers for Smart Anticancer Therapy

Drug delivery to tumor sites using nanotechnology has been demonstrated to overcome the drawbacks of conventional anticancer drugs. Altering the surface shape and geometry of nanocomposites alters their chemical properties, which can confer multiple attributes to nanocarriers for the treatment of ca...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Seung Rim Hwang, Kushal Chakraborty, Jeong Man An, Jagannath Mondal, Hong Yeol Yoon, Yong-kyu Lee
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	pharmaceutical nanocarrier cancer smart polymer lipid Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/ed58df377eec45dca4bb18614f867816
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ed58df377eec45dca4bb18614f867816
record_format	dspace
spelling	oai:doaj.org-article:ed58df377eec45dca4bb18614f8678162021-11-25T18:41:21ZPharmaceutical Aspects of Nanocarriers for Smart Anticancer Therapy10.3390/pharmaceutics131118751999-4923https://doaj.org/article/ed58df377eec45dca4bb18614f8678162021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1875https://doaj.org/toc/1999-4923Drug delivery to tumor sites using nanotechnology has been demonstrated to overcome the drawbacks of conventional anticancer drugs. Altering the surface shape and geometry of nanocomposites alters their chemical properties, which can confer multiple attributes to nanocarriers for the treatment of cancer and their use as imaging agents for cancer diagnosis. However, heterogeneity and blood flow in human cancer limit the distribution of nanoparticles at the site of tumor tisues. For targeted delivery and controlled release of drug molecules in harsh tumor microenvironments, smart nanocarriers combined with various stimuli-responsive materials have been developed. In this review, we describe nanomaterials for smart anticancer therapy as well as their pharmaceutical aspects including pharmaceutical process, formulation, controlled drug release, drug targetability, and pharmacokinetic or pharmacodynamic profiles of smart nanocarriers. Inorganic or organic-inorganic hybrid nanoplatforms and the electrospinning process have also been briefly described here.Seung Rim HwangKushal ChakrabortyJeong Man AnJagannath MondalHong Yeol YoonYong-kyu LeeMDPI AGarticlepharmaceuticalnanocarriercancersmartpolymerlipidPharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1875, p 1875 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pharmaceutical nanocarrier cancer smart polymer lipid Pharmacy and materia medica RS1-441
spellingShingle	pharmaceutical nanocarrier cancer smart polymer lipid Pharmacy and materia medica RS1-441 Seung Rim Hwang Kushal Chakraborty Jeong Man An Jagannath Mondal Hong Yeol Yoon Yong-kyu Lee Pharmaceutical Aspects of Nanocarriers for Smart Anticancer Therapy
description	Drug delivery to tumor sites using nanotechnology has been demonstrated to overcome the drawbacks of conventional anticancer drugs. Altering the surface shape and geometry of nanocomposites alters their chemical properties, which can confer multiple attributes to nanocarriers for the treatment of cancer and their use as imaging agents for cancer diagnosis. However, heterogeneity and blood flow in human cancer limit the distribution of nanoparticles at the site of tumor tisues. For targeted delivery and controlled release of drug molecules in harsh tumor microenvironments, smart nanocarriers combined with various stimuli-responsive materials have been developed. In this review, we describe nanomaterials for smart anticancer therapy as well as their pharmaceutical aspects including pharmaceutical process, formulation, controlled drug release, drug targetability, and pharmacokinetic or pharmacodynamic profiles of smart nanocarriers. Inorganic or organic-inorganic hybrid nanoplatforms and the electrospinning process have also been briefly described here.
format	article
author	Seung Rim Hwang Kushal Chakraborty Jeong Man An Jagannath Mondal Hong Yeol Yoon Yong-kyu Lee
author_facet	Seung Rim Hwang Kushal Chakraborty Jeong Man An Jagannath Mondal Hong Yeol Yoon Yong-kyu Lee
author_sort	Seung Rim Hwang
title	Pharmaceutical Aspects of Nanocarriers for Smart Anticancer Therapy
title_short	Pharmaceutical Aspects of Nanocarriers for Smart Anticancer Therapy
title_full	Pharmaceutical Aspects of Nanocarriers for Smart Anticancer Therapy
title_fullStr	Pharmaceutical Aspects of Nanocarriers for Smart Anticancer Therapy
title_full_unstemmed	Pharmaceutical Aspects of Nanocarriers for Smart Anticancer Therapy
title_sort	pharmaceutical aspects of nanocarriers for smart anticancer therapy
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/ed58df377eec45dca4bb18614f867816
work_keys_str_mv	AT seungrimhwang pharmaceuticalaspectsofnanocarriersforsmartanticancertherapy AT kushalchakraborty pharmaceuticalaspectsofnanocarriersforsmartanticancertherapy AT jeongmanan pharmaceuticalaspectsofnanocarriersforsmartanticancertherapy AT jagannathmondal pharmaceuticalaspectsofnanocarriersforsmartanticancertherapy AT hongyeolyoon pharmaceuticalaspectsofnanocarriersforsmartanticancertherapy AT yongkyulee pharmaceuticalaspectsofnanocarriersforsmartanticancertherapy
_version_	1718410808142069760

Pharmaceutical Aspects of Nanocarriers for Smart Anticancer Therapy

Ejemplares similares